A global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development
About us
SmartCella is a global biotech company pioneering the future of targeted therapies through delivery solutions and advanced therapy development. Founded in 2014, the company is built on globally renowned science and research from Karolinska Institutet in Sweden.
SmartCella combines novel delivery platforms, such as the Extroducer®, an endovascular delivery device that enables direct injection to hard-to-reach organs and tissues, with state-of-the-art development and manufacturing of cell therapies. The company operates in two business segments: Targeted Delivery and Regenerative Medicines. SmartCella’s overarching strategy is to partner with global biotech and pharma companies across all development phases, serving as a partner in bridging the translational gap from early scientific discovery to clinical application. In parallel, SmartCella aims to drive innovation through its proprietary scientific research, addressing critical disease areas such as heart failure, Osteoarthritis and Parkinson’s disease.
The international team consists of scientists, visionary innovators, and experienced business leaders, all dedicated to shaping the future of targeted therapies and delivering life-changing treatments to patients. SmartCella has around 80 employees representing 27 different nationalities.
Our purpose
To bring cures and transform lives for patients in need.
Our Mission
To provide first-in-class delivery platforms, supported by cutting-edge development and manufacturing of therapies.
Our vision
To unlock the full potential of targeted therapies for every patient in need.
SmartCella is privately owned and funded
Key Publication
Migratory and anti-fibrotic programmes define the regenerative potential of human cardiac progenitors
